Takeda, Shire Finally Seal £46bn Deal

Persistence pays off for Takeda as it reaches a confirmed deal for the acquisition of Shire after a dogged pursuit, paving the way for the largest ever M&A transaction both in the Japanese pharma sector and by any Japanese company of an overseas target.

Business teamwork puzzle pieces.
TAKEDA FINALLY SEALS DEAL FOR SHIRE • Source: Shutterstock

Shire PLC has finally accepted a £49.01 per share acquisition offer from persistent suitor Takeda Pharmaceutical Co. Ltd., paving the way for a £46bn ($62bn) deal that will create a new force in the global pharma top 10.

The companies have agreed a deal worth £49.01 per share comprising $30.33 in cash and either 0.839 new Takeda shares...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia